This company has been acquired
Concert Pharmaceuticals Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Wichtige Informationen
-45.4%
Wachstumsrate der Gewinne
-40.8%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | 47.4% |
| Eigenkapitalrendite | -94.8% |
| Netto-Marge | -395.4% |
| Letzte Ertragsaktualisierung | 30 Sep 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Aufschlüsselung der Einnahmen und Ausgaben
Wie Concert Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 22 | 32 | -127 | 22 | 0 |
| 30 Jun 22 | 33 | -125 | 22 | 0 |
| 31 Mar 22 | 33 | -95 | 23 | 0 |
| 31 Dec 21 | 33 | -80 | 23 | 0 |
| 30 Sep 21 | 1 | -66 | 22 | 0 |
| 30 Jun 21 | 2 | -59 | 21 | 0 |
| 31 Mar 21 | 8 | -77 | 20 | 0 |
| 31 Dec 20 | 8 | -75 | 19 | 0 |
| 30 Sep 20 | 8 | -73 | 19 | 0 |
| 30 Jun 20 | 6 | -71 | 19 | 0 |
| 31 Mar 20 | 0 | -77 | 19 | 0 |
| 31 Dec 19 | 1 | -78 | 20 | 0 |
| 30 Sep 19 | 1 | -79 | 21 | 0 |
| 30 Jun 19 | 1 | -79 | 22 | 0 |
| 31 Mar 19 | 1 | -73 | 23 | 0 |
| 31 Dec 18 | 11 | -56 | 23 | 0 |
| 30 Sep 18 | 11 | -41 | 23 | 0 |
| 30 Jun 18 | 11 | 104 | 21 | 0 |
| 31 Mar 18 | 11 | 104 | 21 | 0 |
| 31 Dec 17 | 0 | 95 | 21 | 0 |
| 30 Sep 17 | 0 | 89 | 19 | 0 |
| 30 Jun 17 | 0 | -50 | 18 | 0 |
| 31 Mar 17 | 0 | -50 | 16 | 0 |
| 31 Dec 16 | 0 | -51 | 14 | 0 |
| 30 Sep 16 | 10 | -38 | 14 | 0 |
| 30 Jun 16 | 12 | -35 | 14 | 0 |
| 31 Mar 16 | 15 | 19 | 13 | 0 |
Qualität der Erträge: CNCE is currently unprofitable.
Wachsende Gewinnspanne: CNCE is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: CNCE is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Beschleunigtes Wachstum: Unable to compare CNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: CNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: CNCE has a negative Return on Equity (-94.78%), as it is currently unprofitable.